Skar Pharma UK Ltd

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—4

Registered number: 09734918

		2025		2024
	Notes	£	£	£	£
FIXED ASSETS
Investments	4		670,048		670,048

			670,048		670,048
CURRENT ASSETS
Debtors	5	51,202		50,000
Cash at bank and in hand		6,087		8,270

		57,289		58,270
Creditors: Amounts Falling Due Within One Year	6	(257,062 )		(286,071 )

NET CURRENT ASSETS (LIABILITIES)			(199,773 )		(227,801 )

TOTAL ASSETS LESS CURRENT LIABILITIES			470,275		442,247

Creditors: Amounts Falling Due After More Than One Year	7		(336,260 )		(384,914 )

NET ASSETS			134,015		57,333

CAPITAL AND RESERVES
Called up share capital	8		100		100
Profit and Loss Account			133,915		57,233

SHAREHOLDERS' FUNDS			134,015		57,333

Page 1

Page 2

Skar Pharma UK Ltd

Balance Sheet (continued)

As At 31 October 2025

For the year ending 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Mr Anand Shah

Director

26/05/2026

The notes on pages 3 to 4 form part of these financial statements.

1. General Information

Skar Pharma UK Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 09734918 . The registered office is 4 Nutter Lane, London, E11 2HY.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Freehold

Freehold land is not depreciated

3. Average Number of Employees

Average number of employees, including directors, during the year was: 2 (2024: 2)

4. Investments

	Unlisted
	£
Cost or Valuation
As at 1 November 2024	670,048

As at 31 October 2025	670,048

Provision
As at 1 November 2024	-

As at 31 October 2025	-

Net Book Value
As at 31 October 2025	670,048

As at 1 November 2024	670,048

5. Debtors

	2025	2024
	£	£
Due within one year
Other debtors	50,000	50,000
Amounts owed by subsidiaries	1,202	-

	51,202	50,000

Page 3

Page 4

Skar Pharma UK Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 October 2025

6. Creditors: Amounts Falling Due Within One Year

	2025	2024
	£	£
Bank loans and overdrafts	70,018	70,018
Other creditors	185,244	214,299
Accruals and deferred income	1,800	1,500
Amounts owed to subsidiaries	-	254

	257,062	286,071

7. Creditors: Amounts Falling Due After More Than One Year

	2025	2024
	£	£
Bank loans	336,260	384,914

8. Share Capital

	2025	2024
	£	£
Allotted, Called up and fully paid	100	100